Andreas Varkaris

11PUBLICATIONS
195CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 02, 2026
CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

|Jan 08, 2026
Acquired On-Target Alterations Drive Clinical Resistance to p53-Y220C Reactivators.

Ferran Fece de la Cruz, Andreas Varkaris, Parasvi S Patel

|Sep 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.

James J Harding, Do-Youn Oh, Teresa Macarulla Mercade

|Jan 02, 2025
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.

Rachel O Abelman, Bogang Wu, Haley Barnes

|Jun 19, 2024
AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer.

Mannan Nouri, Andreas Varkaris, Maya Ridinger

|Nov 02, 2023
Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.

Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E Martin

Pageof 2

Frequent Collaborators

5 joint publications

Steven P Balk

4 joint publications

Dejan Juric

3 joint publications

Nicholas J Chevalier

3 joint publications

Bryanna Norden